logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant

< Back

Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant

Drugs

Cancer and Palliative Care

January 2020


Nivolumab in combination with chemotherapy is in clinical development as a neoadjuvant treatment for early-stage (stage IB-IIIA) operable non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Early-stage lung cancer is typically treated with surgery consisting of removing either part of or the whole of the lung, followed by chemotherapy and/or radiotherapy (adjuvant). However, the long-term outlook for patients undergoing this treatment pathway is still poor. Treatment with medicines prior to surgery (neoadjuvant) may provide better long-term survival prospects for patients with early-stage operable NSCLC.
Nivolumab is a medicinal product called an immune checkpoint inhibitor. It is administered by intravenous infusion (injection into the vein) and works by improving the activity of white blood cells (T-cells) thereby increasing the ability of the immune system to kill cancer cells. Nivolumab as a monotherapy is already licensed for a range of advanced cancers where it has shown treatment benefits. If licensed in combination with chemotherapy, it may offer an additional neoadjuvant treatment option for patients with early-stage, operable NSCLC who currently have few well tolerated and effective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts